Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
PLRX Analyst Ratings
Hold
2 Buy
11 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PLRX Stock 12 Month Forecast
Average Price Target
$5.25
▲(288.89% Upside)
| Highest Price Target$17.00 | Average Price Target$5.25 | Lowest Price Target$1.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
03/18/25
Leerink Partners
Reiterated
03/17/25
Wells Fargo
Reiterated
03/04/25
Needham
Downgraded
03/04/25
Oppenheimer
Reiterated
03/04/25
Canaccord Genuity
Reiterated
03/03/25
Citi
Reiterated
03/03/25
Cantor Fitzgerald
Initiated
03/03/25
RBC Capital
Reiterated
03/03/25
Stifel Nicolaus
Downgraded
03/03/25
Piper Sandler
$40→$17
Buy
1159.26%
Upside
Reiterated
03/03/25
Pliant Therapeutics price target lowered to $17 from $40 at Piper SandlerPliant Therapeutics price target lowered to $17 from $40 at Piper Sandler
TD Cowen
―
Buy
―
Reiterated
02/18/25
TD Cowen Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
J.P. Morgan
―
Hold
―
Downgraded
02/10/25
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorganPliant Therapeutics downgraded to Neutral from Overweight at JPMorgan
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
03/18/25
Leerink Partners
Reiterated
03/17/25
Wells Fargo
Reiterated
03/04/25
Needham
Downgraded
03/04/25
Oppenheimer
Reiterated
03/04/25
Canaccord Genuity
Reiterated
03/03/25
Citi
Reiterated
03/03/25
Cantor Fitzgerald
Initiated
03/03/25
RBC Capital
Reiterated
03/03/25
Stifel Nicolaus
Downgraded
03/03/25
Piper Sandler
$40→$17
Buy
1159.26%
Upside
Reiterated
03/03/25
Pliant Therapeutics price target lowered to $17 from $40 at Piper SandlerPliant Therapeutics price target lowered to $17 from $40 at Piper Sandler
TD Cowen
―
Buy
―
Reiterated
02/18/25
TD Cowen Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
J.P. Morgan
―
Hold
―
Downgraded
02/10/25
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorganPliant Therapeutics downgraded to Neutral from Overweight at JPMorgan
PLRX Analyst Recommendation Trends
Rating
Sep 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
17
21
13
15
8
Buy
4
3
4
7
6
Hold
0
0
0
7
19
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
24
17
29
33
Each month's total comprises the sum of three months' worth of ratings.
PLRX Financial Forecast
PLRX Stock Forecast FAQ
What is PLRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Pliant Therapeutics’s 12-month average price target is $5.25.
What is PLRX’s upside potential, based on the analysts’ average price target?
Pliant Therapeutics has 288.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PLRX a Buy, Sell or Hold?
Pliant Therapeutics has a consensus rating of Hold which is based on 2 buy ratings, 11 hold ratings and 0 sell ratings.
What is Pliant Therapeutics’s price target?
The average price target for Pliant Therapeutics is $5.25. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $1.50. The average price target represents 288.89% Increase from the current price of $1.35.
The highest analyst price target is $17.00 ,the lowest forecast is $1.50. The average price target represents 288.89% Increase from the current price of $1.35.
What do analysts say about Pliant Therapeutics?
Pliant Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of PLRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.